Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

<h3>Background</h3> We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC). <h3>Methods</h3> In this phase 1b expansion cohort, patients with mACC and...

Uloženo v:

Podrobná bibliografie
Hlavní autoři:	Christophe Le Tourneau, Christopher Hoimes, Corrine Zarwan, Deborah Jean Lee Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Hariharan Subramanian, Anja von Heydebreck, Vijay Kasturi, Vikram K. Chand, James L. Gulley
Médium:	Artigo
Jazyk:	angličtina
Vydáno:	2018
On-line přístup:	https://doi.org/10.1186/s40425-018-0424-9 https://jitc.bmj.com/content/jitc/6/1/111.full.pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
Autor: Le Tourneau, Christophe, a další
Vydáno: (2018)

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Autor: Keilholz, Ulrich, a další
Vydáno: (2019)

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Autor: Ulrich Keilholz, a další
Vydáno: (2019)

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
Autor: Disis, Mary L., a další
Vydáno: (2019)

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Autor: Heery, Christopher R, a další
Vydáno: (2017)

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Autor: Christopher R. Heery, a další
Vydáno: (2017)

Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab
Autor: Terranova, Nadia, a další
Vydáno: (2022)

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
Autor: Gulley, James L., a další
Vydáno: (2017)

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
Autor: James L. Gulley, a další
Vydáno: (2017)

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial
Autor: Hassan, Raffit, a další
Vydáno: (2019)

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Autor: Kaufman, Howard L., a další
Vydáno: (2018)

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Autor: Howard L. Kaufman, a další
Vydáno: (2018)

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
Autor: Kelly, Karen, a další
Vydáno: (2018)

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
Autor: Karen Kelly, a další
Vydáno: (2018)

First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study
Autor: Sandra P. D’Angelo, a další
Vydáno: (2024)

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
Autor: Benjamin Solomon, a další
Vydáno: (2024)

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Autor: Dirix, Luc Y., a další
Vydáno: (2017)

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Autor: Luc Dirix, a další
Vydáno: (2017)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
Autor: Hawkes, Eliza A., a další
Vydáno: (2021)

Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor
Autor: Hrinczenko, Borys, a další
Vydáno: (2022)

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Autor: Motzer, Robert J., a další
Vydáno: (2020)

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Autor: Robert J. Motzer, a další
Vydáno: (2020)

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
Autor: Mary L. Disis, a další
Vydáno: (2019)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
Autor: D'Angelo, S.P., a další
Vydáno: (2021)

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial
Autor: Herrera, Alex F., a další
Vydáno: (2021)

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
Autor: Guigay, Joël, a další
Vydáno: (2021)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
Autor: Sandra P. D’Angelo, a další
Vydáno: (2021)

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Autor: Vaishampayan, Ulka, a další
Vydáno: (2019)

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Autor: Ulka N. Vaishampayan, a další
Vydáno: (2019)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Autor: D'Angelo, Sandra P, a další
Vydáno: (2020)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Autor: Sandra P. D’Angelo, a další
Vydáno: (2020)

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
Autor: Uemura, Motohide, a další
Vydáno: (2020)

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
Autor: Motohide Uemura, a další
Vydáno: (2019)

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Autor: Patel, Manish R, a další
Vydáno: (2017)

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Autor: Apolo, Andrea B, a další
Vydáno: (2020)

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Autor: Manish R. Patel, a další
Vydáno: (2017)

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Autor: Andrea B. Apolo, a další
Vydáno: (2020)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
Autor: Rocco, Danilo, a další
Vydáno: (2019)

Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design
Autor: Éric Pujade-Lauraine, a další
Vydáno: (2018)

Avelumab: is it time to get excited?
Autor: Marciscano, Ariel E., a další
Vydáno: (2018)